Email this article 
Convalescent Plasma Therapy for COVID-19 is a Challenging Option Review
Abstract
The guiding principle of plasma therapy can be utilized for prophylaxis and treatment reasons, taking into account non-availability of suitable vaccination for prevention or no settled conclusive cure for SARS-CoV-2, plasma therapy is obtaining importance in a current pandemic as one of the treatment options of COVID-19. Despite the fact that, it has been said to be a useful approach in exceptional preliminary studies, convalescent plasma (CP) treatment has various limitations. In this review, an attempt has been made to audit positive viewpoints, negative views and specific limitations of the CP therapy for COVID-19 cases. The outcomes of various studies show that CP treatment would possibly be considered one of the alternatives but while questioning about it as a therapeutic approach, thinking about beneficial aspects, the negative aspects and barriers are to be considered before its administration as a therapeutic agent.
Keywords
Full Text:
PDFReferences
-Dhama, Kuldeep, et al. "Coronavirus disease 2019–COVID-19." Clinical microbiology reviews 33.4 (2020): e00028-20.
-Musso, Didier, and Marion C. Lanteri. "Emergence of Zika virus: where does it come from and where is it going to" The Lancet Infectious diseases 17.3 (2017): 255.
-Vairo, Francesco, et al. "Chikungunya: epidemiology, pathogenesis, clinical features, management, and prevention." Infectious Disease Clinics 33.4 (2019): 1003-1025.
-Vogel, Olivia A., and Balaji Manicassamy. "Broadly protective strategies against influenza viruses: universal vaccines and therapeutics." Frontiers in microbiology 11 (2020): 135.
-Hoenen, Thomas, Allison Groseth, and Heinz Feldmann. "Therapeutic strategies to target the Ebola virus life cycle." Nature Reviews Microbiology 17.10 (2019): 593-606.
-Davis, Matthew R., Erin K. McCreary, and Jason M. Pogue. "That escalated quickly: remdesivir's place in the therapy for COVID-19." Infectious diseases and therapy (2020): 1-12.
-Convertino, Irma, et al. "Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients." Critical Care 24.1 (2020): 1-6.
-Mair-Jenkins, John, et al. "The effectiveness of convalescent plasma and hyper immune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis." The Journal of infectious diseases 211.1 (2015): 80-90.
-Marson, Piero, Andrea Cozza, and Giustina De Silvestro. "The true historical origin of convalescent plasma therapy." Transfusion and apheresis science 59.5 (2020): 102847.
-Cheng, Y., et al. "Use of convalescent plasma therapy in SARS patients in Hong Kong." European Journal of Clinical Microbiology and Infectious Diseases 24.1 (2005): 44-46.
-Franchini, Massimo, et al. "Operational protocol for donation of anti‐COVID‐19 convalescent plasma in Italy." Vox sanguinis (2020).
-Harvala, Heli, et al. "Convalescent plasma therapy for the treatment of patients with COVID‐19: assessment of methods available for antibody detection and their correlation with neutralizing antibody levels." Transfusion Medicine 31.3 (2021): 167-175.
-Phelan, Jody, et al. "Controlling the SARS-CoV-2 outbreak, insights from large scale whole genome sequences generated across the world." BioRxiv (2020).
-Koyama, Takahiko, et al. "Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment." Pathogens 9.5 (2020): 324.
-Zhang, Lizhou, et al. "The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity." BioRxiv (2020).
-Arabi, Yaseen M., et al. "Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia." Emerging infectious diseases 22.9 (2016): 1554.
-. Salazar, Eric, et al. "Relationship between anti-spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma." biorxiv (2020)
-Klein, Sabra L., et al. "Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population." The Journal of clinical investigation 130.11 (2020): 6141-6150
-Madariaga, Maria Lucia L., et al. "Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID‐19 convalescent plasma clinical trial." Journal of internal medicine 289.4 (2021): 559-573.
-Robbiani, Davide F., et al. "Resolving the Functional Significance of BRCA1 RING Domain Missense Substitutions." (2021).
-Knudson, C. Michael, and J. Brooks Jackson. "COVID‐19 convalescent plasma: phase 2." Transfusion (2020).
- Seghatchian, J., and F. Lanza. "Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: a rousing message of clinical benefit to both donors and recipients alike." Transfusion and Apheresis Science 59.3 (2020): 102794.
- COVID, CBER Investigational. "Convalescent plasma-emergency INDs Available at https://www. Fda.gov/vaccines-blood- biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds." (2020).
- An, E. U. "Programme of COVID-19 Convalescent Plasma Collection and Transfusion Guidance on Collection, Testing, Processing, Storage, Distribution and Monitored Use." Ref. Ares (2020): 3256185-23.
- El‐Ekiaby, M., et al. "Solvent‐detergent filtered (S/D‐F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system." Transfusion medicine 20.1 (2010): 48-61.
- Burnouf, T., et al. "Nano filtration of single plasma donations: feasibility study." Vox sanguinis 84.2 (2003): 111-119.
- Wong, Hoi K., et al. "Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection." Transfusion 50.9 (2010): 1967-1971.
- Singh, Yasmin, et al. "Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function." Transfusion 46.7 (2006): 1168-1177.
- Bihm, D. J., et al. "Characterization of plasma protein activity in riboflavin and UV light‐treated fresh frozen plasma during 2 years of storage at− 30° C." Vox sanguinis 98.2 (2010): 108-115.
- Korneyeva, M., et al. "Enveloped virus inactivation by "the caprylate": a robust alternative to solvent-detergent treatment in plasma derived intermediates." Biologicals 30.2 (2002): 153-162.
- Dichtelmüller, H., D. Rudnick, and M. Kloft. "Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution." Biologicals 30.2 (2002): 135-142.
- Goubran, H. A., T. Burnouf, and M. Radosevich. "Virucidal heat‐treatment of single plasma units: a potential approach for developing countries." Haemophilia 6.6 (2000): 597-604.
- Watt, G., et al. "Passive transfer of scrub typhus plasma to patients with AIDS: a descriptive clinical study." Qjm 94.11 (2001): 599-607.
- Vittecoq, D., et al. "Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma." Journal of Infectious Diseases 165.2 (1992): 364-368.
- Vittecoq, D., et al. "Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma." Proceedings of the National Academy of Sciences 92.4 (1995): 1195-1199.
- Zhou, Fei, et al. "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study." The lancet 395.10229 (2020): 1054-1062.
- Zhu, Na, et al. "A novel coronavirus from patients with pneumonia in China, 2019." New England journal of medicine (2020).
- Casadevall, Arturo, and Liise-anne Pirofski. "The convalescent sera option for containing COVID-19." The Journal of clinical investigation 130.4 (2020): 1545-1548.
- Chen, Long, et al. "Convalescent plasma as a potential therapy for COVID-19." The Lancet infectious diseases 20.4 (2020): 398-400.
- Sterlin, Delphine, et al. "IgA dominates the early neutralizing antibody response to SARS-CoV-2." Science translational medicine 13.577 (2021).
- Guo, Li, et al. "Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)." Clinical infectious diseases 71.15 (2020): 778-785.
- Zhu, Na, et al. "A novel coronavirus from patients with pneumonia in China, 2019." New England journal of medicine (2020).
- Long, Quan-Xin, et al. "Antibody responses to SARS-CoV-2 in patients with COVID-19." Nature medicine 26.6 (2020): 845-848.
- Zhao, Juanjuan, et al. "Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019." Clinical infectious diseases 71.16 (2020): 2027-2034.
- Forsythe, J., and R. Cardigan. "Advisory committee on the safety of blood, tissues and organs." Transfusion Medicine (Oxford, England) 19.2 (2009): 57-58.
- Suthar, Mehul S., et al. "Rapid generation of neutralizing antibody responses in COVID-19 patients." Cell Reports Medicine 1.3 (2020): 100040.
- Amanat, Fatima, et al. "A serological assay to detect SARS-CoV-2 seroconversion in humans." Nature medicine 26.7 (2020): 1033-1036.
- Chan, K. H., et al. "Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63." Clinical and Vaccine Immunology 12.11 (2005): 1317-1321.
- Liu, Wei, et al. "Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome." The Journal of infectious diseases 193.6 (2006): 792-795.
- Keil, Shawn D., et al. "Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light‐based photochemical treatment." Vox sanguinis 115.6 (2020): 495-501.
- Andersson, Monique I., et al. "SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus." Welcome open research 5 (2020).
- Tonn, Torsten, et al. "Stability and neutralizing capacity of SARS-CoV-2-specific antibodies in convalescent plasma." The Lancet Microbe 1.2 (2020): e63.
- Sandler, S. Gerald, and Nicole Dodge Zantek. "IgA anaphylactic transfusion reactions. Part II. Clinical diagnosis and bedside management." Immunohematology 20.4 (2004): 234-238.
- Barone, Paul, and Robert A. DeSimone. "Convalescent plasma to treat coronavirus disease 2019 (COVID‐19): considerations for clinical trial design." Transfusion (2020).
- Shen, Chenguang, et al. "Treatment of 5 critically ill patients with COVID-19 with convalescent plasma." Jama 323.16 (2020): 1582-1589.
- Duan, Kai, et al. "Effectiveness of convalescent plasma therapy in severe COVID-19 patients." Proceedings of the National Academy of Sciences 117.17 (2020): 9490-9496.
- Ye, Mingxiang, et al. "Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China." Journal of medical virology 92.10 (2020): 1890-1901.
- Pei, Shiyao, et al. "Convalescent plasma to treat COVID-19: Chinese strategy and experiences." medRxiv (2020).
- Zhang, Libo, et al. "Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19." Aging (Albany NY) 12.8 (2020): 6536.
- Zeng, Qing-Lei, et al. "Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019." The Journal of infectious diseases 222.1 (2020): 38-43.
- Kong, Yujie, et al. "Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma." Transfusion and Apheresis Science 59.5 (2020): 102820.
- Ahn, Jin Young, et al. "Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea." Journal of Korean medical science 35.14 (2020).
- Abdullah, Hadi Mohammed, et al. "Severe refractory COVID-19 patients responding to convalescent plasma; A case series." Annals of medicine and surgery 56 (2020): 125-127.
- Olivares-Gazca, Juan C., et al. "Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study." Revista de investigación clínica 72.3 (2020): 159-164.
- Erkurt, Mehmet Ali, et al. "Life-saving effect of convalescent plasma treatment in covid-19 disease: clinical trial from eastern Anatolia." Transfusion and Apheresis Science 59.5 (2020): 102867.
- Jiang, Jipin, et al. "Convalescent plasma therapy: helpful treatment of COVID‐19 in a kidney transplant recipient presenting with "the serve" clinical manifestation and complex complications." Clinical transplantation (2020).
- Figlerowicz, Magdalena, et al. "First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia." Transfusion and Apheresis Science 59.5 (2020): 102866.
- Mira, Estefanía, et al. "Rapid recovery of a SARS-CoV-2–infected X-linked agammaglobulinemic patient after infusion of COVID-19 convalescent plasma." The Journal of Allergy and Clinical Immunology: In Practice 8.8 (2020): 2793-2795.
- Clark, Evangéline, et al. "Convalescent plasma for persisting COVID‐19 following therapeutic lymphocyte depletion: a report of rapid recovery." British journal of haematology (2020).
- Hegerova, Livia, et al. "Use of convalescent plasma in hospitalized patients with COVID-19: case series." Blood 136.6 (2020): 759-762.
- Hartman, William R., Aaron S. Hess, and Joseph P. Connor. "Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest." Translational medicine communications 5.1 (2020): 1-6.
- Çınar, Olgu Erkin, et al. "Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis." Transfusion and Apheresis Science 59.5 (2020): 102821.
- Anderson, Jonathon, et al. "The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: a case report." Case reports in women's health 27 (2020): e00221.
- Niu, Alex, et al. "COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma." Bone marrow transplantation 55.12 (2020): 2354-2356.
- Li, Kening, et al. "Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19." Nature communications 11.1 (2020): 1-11.
- Liu, Sean TH, et al. "Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study." Nature medicine 26.11 (2020): 1708-1713.
- Li, Ling, et al. "Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial." Jama 324.5 (2020): 460-470.
- Labarrere, Carlos A., et al. "Early prediction of cardiac allograft vasculopathy and heart transplant failure." American Journal of Transplantation 11.3 (2011): 528-535.
- Casadevall, A., and L. Pirofski. "March 2020, posting date. The convalescent sera option for containing COVID-19." J Clin Invest https://doi. Org/10.1172/JCI138003 (13).
-Kraft, Colleen S., et al. "The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States." Clinical infectious diseases 61.4 (2015): 496-502.
-Kraft, Colleen S., et al. "The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States." Clinical infectious diseases 61.4 (2015): 496-502.
-Duan, Kai, et al. "Effectiveness of convalescent plasma therapy in severe COVID-19 patients." Proceedings of the National Academy of Sciences 117.17 (2020): 9490-9496.
- Sullivan, H. Cliff, and John D. Roback. "Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic." Transfusion medicine reviews 34.3 (2020): 145-150.
-Zhou, X. Z., et al. "Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area." Zhonghua yi xue za zhi 83.12 (2003): 1018-1022.
- Anudeep, T. C., et al. "Convalescent Plasma as a plausible therapeutic option in nCOVID-19–A Review." J Clin Trials 10.409 (2020): 2167-0870.
- Boeckh, M., and A. P. Geballe. "Journal of Clinical Investigation." JCI 121.5 (2011): 1673-1680.
-Roback, John D., and Jeannette Guarner. "Convalescent plasma to treat COVID-19: possibilities and challenges." Jama 323.16 (2020): 1561-1562.
-Gajic, Ognjen, et al. "Transfusion-related acute lung injury in the critically ill: prospective nested case-control study." American journal of respiratory and critical care medicine 176.9 (2007): 886-891.
-Uhr, Jonathan W., and Joyce B. Baumann. "Antibody formation: I. The suppression of antibody formation by passively administered antibody." The Journal of experimental medicine 113.5 (1961): 935-957.
- Herman, A. O., D. G. Fairchild, and J. E. Hefner. "SARS-CoV-2 antibodies undetectable in some recovered patients." NEJM Journal Watch. April 13 (2020).
- Bi, Qifang, et al. "Epidemiology and Transmission of COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close contacts." MedRxiv (2020).
-Zhang, Bin, et al. "Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection." Chest 158.1 (2020): e9-e13.
- An, E. U. "Programme of COVID-19 Convalescent Plasma Collection and Transfusion Guidance on Collection, Testing, Processing, Storage, Distribution and Monitored Use." Ref. Ares (2020): 3256185-23.
DOI: http://dx.doi.org/10.52155/ijpsat.v28.2.3522
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Maged Naser, Mohamed M.Nasr, Lamia H. Shehata
This work is licensed under a Creative Commons Attribution 4.0 International License.